Investor FAQs

Show all

Achillion's research and development operations are located at 300 George Street in New Haven, Connecticut. The company’s corporate office is located at 1777 Sentry Parkway West in Blue Bell, PA.
Achillion Pharmaceuticals, Inc. was incorporated in 1998 and began operations in 2000.
Achillion went public on October 25th, 2006 at an IPO price of $11.50 per share.
Achillion Pharmaceuticals is listed on the NASDAQ stock exchange under the symbol ACHN.
The CUSIP number for Achillion common stock is 00448Q 20 1.
Most Achillion shareholders hold their stock in "Street Name" (i.e. their broker) and do not receive stock certificates. If you would like to request a stock certificate be mailed to you, contact your broker or Computershare Shareholder Services.
The latest SEC Form 10-Q or 10-K lists current shares outstanding. These documents are available on this website under SEC Filings.
Achillion does not pay cash dividends on its common stock and does not anticipate doing so in the foreseeable future.
Achillion's common stock can be bought or sold through a stockbroker or financial institution that offers brokerage services.
Achillion's independent auditors are PricewaterhouseCoopers LLP.
Achillion's legal counsel is Wilmer Cutler Pickering Hale and Dorr LLP.
Computershare Shareholder Services
P.O. Box 30170
College Station, TX 77842-3170
(781) 575-2879
The Company's fiscal year begins on January 1 and ends on December 31.
Please go to our section entitled Analyst Coverage for a listing of those firms and analysts that cover Achillion.
Please see the list and biographies of our Directors in the Board of Directors section of the Achillion website.
The Board of Directors has the following standing Committees: Audit, Compensation, Compliance, Nominating and Strategy. The Charters for each of these Committees can be found  in the Corporate Governance Section of Achillion's website.
You may call Brian DiDonato, Vice President, Investor Relations and Corporate Communications at (203) 752-5452 or email for assistance with Investor Relations questions.